Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of non-Hodgkin lymphomas that are considered incurable. The role of allogeneic hematopoietic SCT (HSCT) in the treatment of CTCL is not well defined but may provide potent graft-vs-lymphoma (GVL) activity independent of the conditioning therapy. We present outcomes of 12 extensively-pretreated patients with CTCL who underwent allogeneic HSCT using, most commonly, a reduced intensity conditioning regimen. Median age at diagnosis of CTCL was 49 years, and median time to transplantation from diagnosis was 3.3 years. Transplantation induced and maintained CR in six patients with active disease, supporting the presence of a GVL effect. TRM was low, and 42% of patients were alive and disease-free a median duration of 22 months after transplant. Two patients showed strong and direct evidence of a GVL-effect with a direct response to withdrawal of immunosuppression or to donor leukocyte infusion. Our data show that HSCT can provide longterm disease control in patients with advanced CTCL, which otherwise was refractory to immunotherapy and chemotherapy.
Introduction
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of non-Hodgkin lymphomas; the majority of cases are Mycosis fungoides (MF) and/or Sezary syndrome (SS); the remainder include a variety of subtypes which vary greatly in clinical behavior. All forms of CTCL are generally considered to be incurable. Although mycosis fungoides may have a relatively indolent course, 1 once the disease has progressed beyond early stages, it can behave in a highly aggressive manner. SS (circulating lymphoma cells greater than 1000/mm 3 and greater than 10% of peripheral blood leukocytes) has a median survival time of 31 months. 2 Although there are numerous therapies available to treat CTCL, including newer biological therapies, CTCL is highly responsive to immune manipulation. 3, [4] [5] [6] [7] Responses to IFN a, IFN g and IL-12 highlight the fact that CTCL is influenced by host immune status. 8, 9 Conventional treatments are at best temporizing with aggressive disease, 10 and high-dose chemotherapy with autologous hematopoietic SCT (HSCT) for MF and SS has had disappointing results. 11 For many diseases, allogeneic HSCT is an ideal form of immunotherapy; however, the role for allogeneic HSCT in CTCL is not well defined. Allogeneic transplant is successful in part because of the graft-vs-lymphoma (GVL) effect of the donor graft, independent of the conditioning regimen. 12 Several small series describe durable remissions during allogeneic HSCT after both reduced intensity conditioning (RIC) and myeloablative conditioning. [13] [14] [15] Donor leukocyte infusion (DLI) has also been reported to be effective in producing a GVL effect, but only when combined with several other modalities of therapy including chemotherapy. 14 Nevertheless, long-term remissions, particularly in the setting of RIC allogeneic transplant, and the observation of responses with withdrawal of immunosuppression support the presence of a potent GVL effect. 14, 15 We showed the outcomes of 12 consecutive patients who underwent allogeneic HSCT using, most commonly, a RIC regimen for this rare lymphoid malignancy at our institution. The high response rate, durable remissions and direct GVL induction with DLI, all support a potent GVL-effect in patients with MF and SS from allogeneic HSCT.
Materials and methods
A retrospective review was performed using the University of Pennsylvania BM transplant database to identify all the patients who underwent allogeneic HSCT for cutaneous T cell lymphoma. In all, 12 patients were identified who underwent transplantation between 2004-2010. A chart review was performed to obtain data about diagnosis, staging, treatment, transplantation and outcomes. This study was reviewed and approved by the institutional review board at the University of Pennsylvania.
Patient selection
Patients were referred for transplantation because of poor prognosis or progression after conventional therapy. They were generally heavily pretreated, having received a median of eight non-chemotherapy and two chemotherapy-based treatment modalities before being transplanted. Treatments are listed in Table 1 . Only three patients were in CR at the time of transplant, whereas one had minimal residual disease detectable by flow cytometry in the BM, four had chemo-responsive active disease and four had progressive active disease.
Transplantation
Seven of the patients (Patient no. 1-no. 7) had HLAidentical sibling donors, whereas unrelated donors were identified for the rest. Of these, donors for four patients (Patient no. 8, Patient no. 10-no. 12) were well-matched by high resolution molecular typing at HLA-A, B, C, DR and DQ, whereas patient no. 9 had a single Ag mismatch.
RIC with fludarabine (120 mg/m 2 over 4 days) and BU (6.4 mg/kg over 2 days), or fludarabine (same dose) and CY (3 g/m 2 ) was used in 10 cases. Conventional myeloablative conditioning with CY (120 mg/kg over 2 days) and TBI (1200 cGy fractionated) in six doses over 3 days was used in two young patients with excellent performance status and active disease prior to transplantation (see Table 1 ). GVHD prophylaxis consisted of a calcineurin inhibitor and MTX in all patients.
Statistics
OS was measured as time from HSCT to death from any cause. EFS was measured as time from HSCT to relapse, progression or death from any cause, whichever occurred first. Probabilities of OS and EFS, and survival curves, were generated using Kaplan-Meier estimates. 16 Statistical analysis was performed using Statview.
Results

Patient characteristics
Patient characteristics, diagnosis and stage are shown in Table 1 . Patients were staged using the ISCL/EORTC TNM staging system. 17 There were five male and seven female patients with a median age of 49 years at diagnosis of CTCL (range 40-61 years). Of the 12 patients, five had MF (stages IIB, IIB, IIIB, IVA2, IVB; two with nodal transformation), four had SS (one stage IVA1, three IVA2; one with nodal transformation) and three had Gamma-delta T-cell lymphoma (all T3b). Median time to transplantation from diagnosis was 3.3 years (range 0.5-7 years), with a median age of 53 years (range 41-61 years) at transplantation. The median follow-up is 15 months (range 1-45 months) for all patients and 24 months (range 13-45 months) for patients who are currently alive.
Engraftment
Neutrophil engraftment occurred with an ANC 4500 at a median of 13 days (range 10-34 days) after HSCT. At day 100 after HSCT in 10 evaluated patients, median whole blood chimerism was 97%. Patient no. 1 was diagnosed with CNS PTLD within 100 days of HSCT and lost her graft after rapid tapering of immunosuppression. Patient no. 8 had decreasing donor chimerism 15 months after HSCT, and received DLI with subsequent achievement of 100% donor chimerism. Individual chimerism trends are described in Table 2 .
Response and survival outcomes
The outcomes of all patients are shown in Figure 1 . patients relapsed after achieving CR between 4-13 months after HSCT, but two of them re-achieved and maintained CR, one after tapering immunosuppression and the other after receiving DLI (without additional chemotherapy). Thus, of the 10 patients who survived to 100 days, five are alive in CR at last contact and one is alive with active disease.
The median EFS for all points was 5.3 months (Figure 2a ). This underestimates achievement of CR, because two patients were able to relapse and maintain CR as mentioned above. Kaplan-Meier estimated that 2-year OS was 58%, and estimated median OS was 37 months (Figure 2b) .
GVHD
In all, 9 of 12 patients developed acute GVHD, with four developing Grade III and IV GVHD. GVHD was the cause of death in one patient. Acute and chronic GVHD are detailed in Table 3 .
GVL activity
Patient no. 4 received DLI (2.2 Â 10 8 nucleated cells/kg) at the time of relapse (after tapering off immunosuppression) 13 months after HSCT, and achieved CR that is persistent for 26 months after DLI. Patient no. 12 was on Tacrolimus at the time of relapse, and achieved CR with discontinuation of immunesuppression. The patient remains in CR 8 months later. This provides clear evidence for a GVL effect, as none of these patients received any accompanying chemo/systemic therapy that might explain achievement and maintenance of CR.
Of note, patient no. 7 received DLI (1.5 Â 10 8 nucleated cells/kg) 6 months after HSCT, with minimal effect on disease progression. Patient no. 8 received DLI (10 7 nucleated cells/kg) 15 months after HSCT for decreasing donor chimerism (no evidence of relapse), with a subsequent achievement of 100% donor chimerism and continued CR.
Discussion
Although CTCL is often an indolent lymphoma, with numerous effective treatment options, it is generally incurable, and most patients eventually fail chemotherapy and biological therapies and will die of their disease. 18 The prognosis is especially poor for patients with transformed CTCL and for patients who fail conventional therapy. 19 Newer treatments like denileukin diftitox, 20 vorinostat 3 and romidepsin 7 have recently shown promising results.
High-dose therapy and autologous HSCT has been disappointing, and early relapses are common. 11 The role of allogeneic HSCT in CTCL is unclear. A recent retrospective study from the EBMT included a heterogeneous group of patients who received both myeloablative and RIC regimens with estimated 3-year survival of 54%. 21 Three other small reports further support the role of allogeneic HSCT in CTCL. Molina et al. 13 described eight patients with MF/SS who were treated with RIC:SCT and six patients remained alive without disease 33-108 months after transplant. Duvic et al. 14 described outcomes in 19 recipients of an intensive though RIC that included total skin electron beam irradiation followed by allogeneic transplant, with 11 patients achieving sustained remissions, and several achieving stable disease after a combination of DLI, immunosuppression withdrawal and/or chemotherapy. Delioukina et al. 15 also showed similarly encouraging results for RIC:SCT in 11 patients with CTCL, and observed no further relapses/deaths after the first 18 months of HSCT.
We report our experience using, most commonly, a RIC regimen followed by allo-SCT in 12 consecutive patients with extensively pretreated advanced CTCL. Response rates were high. Treatment-related mortality was low. Two patients who did not respond died from infectious complications within 100 days of transplant. GVHD accounted for death in one patient. The most common cause of death was disease progression in five patients.
In all, 42% of our patients were alive and disease-free with median duration of 22 months after transplant. Although this percentage seems lower than that of other reports, it is difficult to compare patients across different retrospective studies. Furthermore, our outcomes provide strong and direct support for the presence of a GVL effect in CTCL; one patient achieved CR after DLI alone for relapse and a second achieved sustained remission after withdrawal of immunosuppression.
Despite the limitations associated with this retrospective review of small numbers of patients, our outcomes support the presence of a meaningful GVL effect associated with RIC allo-SCT. With small numbers of patients it was not possible to associate the occurrence of GVHD.
Our experience shows that RIC HSCT can provide longterm disease control in patients with advanced CTCL who are otherwise refractory to immunotherapy and chemotherapy. Ideally, prospective studies will further define the role of allogeneic HSCT in this disease. However, given the limited TRM, consideration for earlier transplant should be given, with a focus on the use of newer agents for achieving minimal residual disease prior to transplant. Interventions to decrease the risk of relapse should be considered, including the possibility of maintenance immunotherapy and/or planned DLI.
